Biocon Limited — Investor Meet, 14-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Biocon's Q4 FY26 earnings call highlighted resilient performance, with operating revenue up 10% YoY (adjusted) and EBITDA increasing 29% YoY to ₹1,073 Cr, achieving a 23% margin. Full year FY26 saw 13% revenue growth and 25% EBITDA growth. Biosimilars revenue grew 12% YoY, driven by advanced markets, while Generics (ex-lenalidomide) rose 13%. Management confirmed the major investment phase is complete, now prioritizing execution, margin expansion, and deleveraging, with net debt reduced to $1.1-1.2 billion. Upcoming biosimilar launches like aflibercept and Aspart in H2 FY27, alongside scaling products such as Yesintek, are expected to drive progressive growth. The company is poised for consistent performance from its strengthened foundation.